Tenpoint Therapeutics

Highlights ⭐

• Solving the problem: Vision loss is a growing cause of disability, with the global prevalence of age-related macular degeneration expected to reach 288 million individuals globally by 2040. In virtually every ocular disease, vision deteriorates due to the damage or loss of cells in the eye. Since, in many cases, the cells of the eye, such as photoreceptors, retinal pigment epithelium, and retinal ganglion cells, are unable to regrow on their own, replacement through engineered cell-based therapeutics is the only treatment modality with the potential to dramatically improve vision. This is particularly true in later-stage disease, where a significant proportion of tissue/cells are already lost, leaving no anatomy to benefit from conventional treatments, including gene therapies. 🔗
• Years in the making: Tenpoint was established based on the pioneering work of its scientific founders from Moorfields Eye Hospital, University College London Institute of Ophthalmology, Institut de la Vision in Paris, and the University of Washington, who have developed engineered cell-based therapeutics and performed translational research to establish proof-of-concept. Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
• Experienced team: Tenpoint is led by renowned experts in both regenerative medicine and ophthalmology. As CEO, Eddy Anglade, MD brings decades of experience in clinical development in ophthalmic diseases with significant unmet needs. Vanessa King, PhD, Tenpoint's founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor. Tenpoint previously named ophthalmology innovator David Guyer, MD, to chair its board. Dr. Guyer currently serves as CEO of EyeBio and previously served as Executive Chairman of IVERIC bio, a company he co-founded under the name Ophthotech. As co-founder, CEO and director of Eyetech Pharmaceuticals, he oversaw the development and commercialization of Macugen (pegaptanib sodium), the first anti-VEGF pharmacological treatment approved by the FDA for the treatment of wet AMD.